Trilaciclib to Protect Bone Marrow in Limited-Stage Small Cell Lung Cancer
Compares trilaciclib with placebo in adults with limited-stage small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Key facts
- Where
- A Coruna, Badalona, Barcelona, Córdoba, Elche, Lleida, Madrid, Málaga, Móstoles, Reus, San Cristóbal de La Laguna, Santiago de Compostela, Sevilla, Torrejón de Ardoz, Valencia, Vigo, and Zaragoza, SpainSee the 21 sites
- Phase
- Phase 3
Where in Spain
- Fundacion Centro Oncologico Regional De Galicia Jose Antonio Quiroga Y PineyroA Coruna, SpainTaking people
- Institut Catala d'OncologiaBadalona, SpainTaking people
- Hospital Quirónsalud BarcelonaBarcelona, SpainTaking people
- Pratia Mcc Clinic Spain S.L.Barcelona, SpainTaking people
- Hospital Universitario Reina SofiaCórdoba, SpainTaking people
- Hospital Universitario del VinalopoElche, SpainTaking people
- Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De LleidaLleida, SpainTaking people
- Hospital Moncloa Grupo Hla S.A.Madrid, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
- Hospital Universitario La PazMadrid, SpainTaking people
- MD Anderson Cancer CenterMadrid, SpainTaking people
- Hospital Universitario Virgen de la VictoriaMálaga, SpainTaking people
- Hospital Universitario Rey Juan CarlosMóstoles, SpainTaking people
- Salut Sant Joan de ReusReus, SpainTaking people
- Hospital Universitario de CanariasSan Cristóbal de La Laguna, SpainTaking people
- Complexo Hospitalario Universitario De SantiagoSantiago de Compostela, SpainTaking people
- Hospital Universitario Virgen De ValmeSevilla, SpainTaking people
- Hospital Universitario de TorrejonTorrejón de Ardoz, SpainTaking people
- Fundación Instituto Valenciano de OncologíaValencia, SpainTaking people
- Hospital Alvaro CunqueiroVigo, SpainTaking people
- Hospital Universitario Miguel ServetZaragoza, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pharmacosmos A/S
- Trial code
- NCT07473128EU 2025-525026-35-00
- Record updated
- 2 October 2026
- Original description
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:Read full original descriptionShow less
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:
Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?
Participants will be randomised to receive either trilaciclib or placebo.
Inclusion: Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer; Complete recovery from prior anti-tumor surgical procedures; Measurable and evaluable disease through tumor assessment; Willingness to participate and sign informed consent form.
Exclusion: Extensive Stage Small Cell Lung Cancer; Active cardiovascular disease; Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations; Pregnant or nursing women.